Long-term update of the 24954 EORTC phase III trial on larynx preservation

B. Henriques De Figueiredo*, C. Fortpied, J. Menis, Jean-Louis Lefebvre, Luigi Barzan, D. de Raucourt, L. Geoffrois, L. Giurgea, P. Hupperets, René C Leemans, Lisa Licitra, F. Rolland, M.E. Tesselaar, J B. Vermorken, Vincent Gregoire

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The long-term results of the EORTC 24954 trial comparing sequential versus alternating chemotherapy and radiotherapy (RT) for patients with locally advanced laryngeal and hypopharyngeal cancer are reported. From 1996 to 2004, 450 patients were randomly assigned (1–1) to a sequential arm (SA = induction cisplatin-5fluorouracil followed by a 70Gy-RT for the responders or a total laryngectomy and post-operative RT for the non-responders) and an alternating arm (AA = cisplatin-5fluorouracil alternated with three 2-week courses of 20 Gy-RT for a total dose of 60 Gy). Median follow-up was 10.2 years. Ten-year survival with functional larynx (primary end-point) and overall survival were similar in both arms (18.7% and 33.6% in SA versus 18.3% and 31.6% in AA). Late toxicity was also similar; however, a trend for higher larynx preservation and better laryngeal function was observed in AA.
Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalEuropean Journal of Cancer
Publication statusPublished - Sept 2016


  • Larynx preservation
  • Radiochemotherapy
  • Late toxicity


Dive into the research topics of 'Long-term update of the 24954 EORTC phase III trial on larynx preservation'. Together they form a unique fingerprint.

Cite this